Intra-Cellular Therapies Q2 2023 Earnings Report

Intra-Cellular Therapies EPS Results

• Actual EPS: -$0.45
• Consensus EPS: -$0.62
• Beat/Miss: Beat by +$0.17
• One Year Ago EPS: -$0.92

Intra-Cellular Therapies Revenue Results

• Actual Revenue: $110.80 million
• Expected Revenue: $106.45 million
• Beat/Miss: Beat by +$4.35 million
• YoY Revenue Growth: +99.40%

Intra-Cellular Therapies Announcement Details

• Quarter: Q2 2023
• Date: 8/3/2023
• Time: Before Market Opens

Intra-Cellular Therapies (NASDAQ:ITCI), a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.